[
    [
        {
            "time": "",
            "original_text": "国务院出台鼓励政策支持优质仿制药 4股总动员",
            "features": {
                "keywords": [
                    "国务院",
                    "鼓励政策",
                    "优质仿制药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "国务院出台鼓励政策支持优质仿制药 4股总动员",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[买入评级] 医药生物行业投资策略：进口抗癌药关税政策无需过度放大 依然看好国内创新药企业",
            "features": {
                "keywords": [
                    "买入评级",
                    "医药生物",
                    "投资策略",
                    "进口抗癌药",
                    "关税政策",
                    "创新药企业"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级] 医药生物行业投资策略：进口抗癌药关税政策无需过度放大 依然看好国内创新药企业",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报: “互联网+医疗健康”措施确定, 覆盖医疗多方市场",
            "features": {
                "keywords": [
                    "医药生物",
                    "互联网+医疗健康",
                    "措施确定",
                    "多方市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业周报: “互联网+医疗健康”措施确定, 覆盖医疗多方市场",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]